NORTH CHICAGO - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration ( FDA) has granted two Breakthrough Therapy Designations (BTDs) for telisotuzumab adizutecan (Temab-A; ABBV-400 ...
At the University of Missouri, plant scientist Ron Mittler is rewriting the playbook for how scientists study life by asking ...
SeaStar Medical Holding Corp. ( ICU ), a commercial-stage healthcare company, said the U.S. FDA has granted Breakthrough Device Designation to its Selective Cytopheretic Device (SCD) therapy for ...
NSCLC development advances after FDA Breakthrough Therapy Designation for previously treated EGFR wild-type, c-Met disease.
Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults ...
Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the U.S. Food and Drug Administration ...
Reinsurance Group of America upgraded to Buy after strong underwriting and investment returns. See here for a detailed ...
EURETINA Innovation Spotlight – Inherited and Rare Retinal Diseases Title: Belite Bio Company Overview Presenter: Hendrik Scholl, M.D., Chief Medical Officer, Belite Bio Date and Time: September 30, ...
Global Medical Device Clinical Trials Market was valued at USD 17.52 Billion in 2025 and is expected to grow at 6.58% CAGR to reach USD 33.14 Billion by 2035.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to ...
Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results